Table 2.
Baseline Clinical Characteristics for Patients With RR-NSVT Versus No RR-NSVT
| Baseline Characteristic | RR-NSVT (n = 186) |
No RR-NSVT (n = 625) |
p Value* |
|---|---|---|---|
| Age (yrs) | 58 (50, 67) | 61 (53, 70) | 0.024 |
| Women | 17% (31) | 25% (154) | 0.020 |
| Nonwhite race | 27% (51) | 21% (132) | 0.076 |
| Weight (lb) | 192 (165, 226) | 189 (162, 217) | 0.14 |
| NYHA functional class III | 35% (66) | 31% (191) | 0.21 |
| Ischemic HF etiology | 40% (74) | 55% (346) | 0.001 |
| Ejection fraction (%) | 20 (18, 26) | 25 (20, 30) | 0.001 |
| Diabetes | 23% (42) | 33% (205) | 0.007 |
| Pulmonary disease | 22% (40) | 21% (131) | 0.87 |
| Hyperlipidemia | 42% (78) | 55% (343) | 0.002 |
| Hypertension | 56% (104) | 54% (337) | 0.63 |
| Atrial fibrillation/flutter | 18% (33) | 17% (106) | 0.80 |
| Syncope | 8% (15) | 6% (37) | 0.31 |
| QRS duration ≥120 ms | 41% (77) | 41% (259) | 0.99 |
| Systolic blood pressure (mm Hg) | 118 (106, 132) | 118 (104, 130) | 0.49 |
| Diastolic blood pressure (mm Hg) | 70 (62, 80) | 70 (60, 80) | 0.91 |
| Heart rate (beats/min) | 76 (68, 88) | 73 (64, 84) | 0.008 |
| Serum sodium (mEq/l) | 139 (137, 141) | 139 (137, 141) | 0.52 |
| Serum creatinine (mg/dl) | 1.10 (0.90, 1.30) | 1.10 (1.00, 1.40) | 0.34 |
| ACE inhibitors or ARBs | 98% (182) | 93% (584) | 0.011 |
| Beta-blockers | 59% (110) | 73% (455) | 0.001 |
| Digoxin | 72% (133) | 66% (411) | 0.14 |
| Aspirin | 51% (95) | 60% (372) | 0.041 |
| Statins | 26% (49) | 41% (256) | 0.001 |
| Aldosterone antagonist | 15% (27) | 20% (126) | 0.076 |
Values are median (25th, 75th percentile) or % (n).
*
Likelihood ratio chi-square tests for categorical variables and Wilcoxon rank sum tests for continuous variables.
ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; HF = heart failure; NYHA = New York Heart Association; RR-NSVT = rapid-rate nonsustained ventricular tachycardia.